retatrutide phase 2 nejm 2023 obesity trial results 🤔 Adults with type diabetes (T2D) and lose less weight on EVERY GLP-1 drug compared to those without diabetes, consistently ~5% less. Now that we have retatrutide's TRIUMPH-2 data today Among participants 4 to 66

In both studies, nasal glucagon adequately increased blood glucose levels

Today, most GLP-1 drugs are delivered via refrigerated injectable pens or daily syringes, approaches that can be costly, inconvenient, and uncomfortable for patients

This is where the majority of reported adverse outcomes originate

Across several GLP-1 trials, roughly 25-40% of the total weight lost has come from lean tissue

Intervention phases across different stages of healing

PLP acts as a cofactor for numerous enzymes involved in amino acid metabolism, particularly those associated with neurotransmitter synthesis, like serotonin, dopamine, and gamma-aminobutyric acid (GABA) (5759)